OverviewSuggest Edit

Endologix, Inc. is singularly focused on providing innovative, minimally invasive technologies for aortic disorders. The Company's product offering includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Designed around key issues with challenging anatomies, difficult access, and aneurysm sealing, Endologix products have been clinically proven in delivering positive patient outcomes. 

TypePublic
Founded1992
HQIrvine, CA, US
Websiteendologix.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Dec 2018)528(-21%)
Job Openings12
Revenue (FY, 2019)$143.4 M(-8%)
Share Price (Oct 2020)$0(-24%)
Cybersecurity ratingCMore

Key People/Management at Endologix

John Onopchenko

John Onopchenko

Chief Executive Officer and Director
Cindy Pinto

Cindy Pinto

Interim Chief Financial Officer
Reyna Fernandez

Reyna Fernandez

Chief Human Resources Officer
Jeff Brown

Jeff Brown

Chief Operations Officer
Michael Chobotov

Michael Chobotov

Chief Technology Officer
Jeffry Fecho

Jeffry Fecho

Chief Quality Officer
Show more

Endologix Office Locations

Endologix has offices in Irvine, Santa Rosa, Rosmalen, 's-Hertogenbosch and in 1 other location
Irvine, CA, US (HQ)
2 Musick
Santa Rosa, CA, US
3910 Brickway Blvd
's-Hertogenbosch, NL
Europalaan 30
Rosmalen, NL
40 Burgemeester Burgerslaan
Singapore, SG
1 Gateway Dr, #07-01 Westgate Tower
Show all (5)

Endologix Financials and Metrics

Endologix Revenue

Embed Graph
View revenue for all periods
Endologix's revenue was reported to be $143.37 m in FY, 2019
USD

Revenue (Q2, 2020)

24.8m

Gross profit (Q2, 2020)

14.2m

Gross profit margin (Q2, 2020), %

57%

Net income (Q2, 2020)

(26.1m)

EBIT (Q2, 2020)

(17.3m)

Market capitalization (1-Oct-2020)

4.2m

Closing stock price (1-Oct-2020)

0.0

Cash (30-Jun-2020)

18.5m

EV

382.2m
Endologix's current market capitalization is $4.2 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

192.9m181.2m156.5m143.4m

Revenue growth, %

26%(6%)(14%)

Cost of goods sold

69.1m59.8m64.6m52.3m

Gross profit

123.8m121.3m91.9m91.1m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

42.6m48.6m46.0m42.3m44.7m34.8m35.6m36.2m35.8m28.5m24.8m

Cost of goods sold

14.0m16.3m16.9m14.0m15.1m12.1m12.4m13.3m12.7m13.4m10.7m

Gross profit

28.6m32.2m29.1m28.3m29.6m22.6m23.2m23.0m23.1m15.1m14.2m

Gross profit Margin, %

67%66%63%67%66%65%65%63%64%53%57%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

26.1m58.0m23.5m41.6m

Accounts Receivable

1.8m22.4m

Inventories

41.2m45.2m30.4m26.4m

Current Assets

129.8m143.1m78.9m93.7m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

15.5m81.6m74.6m48.0m35.6m38.3m9.7m50.9m46.6m40.9m18.5m

Accounts Receivable

952.0k390.0k21.9m21.7m19.0m11.1m

Prepaid Expenses

2.3m2.1m

Inventories

42.7m43.6m42.7m45.8m42.8m42.3m30.2m30.7m30.9m24.5m25.9m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(154.7m)(66.4m)(79.7m)(64.8m)

Depreciation and Amortization

9.1m9.1m8.0m6.9m

Inventories

3.5m(3.0m)13.8m3.6m

Accounts Payable

(5.2m)(1.8m)(1.3m)3.1m
Quarterly
USDFY, 2016

Revenue/Employee

246.7k

Financial Leverage

3.2 x
Show all financial metrics

Endologix Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Endologix Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Endologix Online and Social Media Presence

Embed Graph

Endologix News and Updates

United States // Endologix, Inc. to Present at the SVB Leerink Global Healthcare Conference

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-li…

Endologix Blogs

Endologix LLC Announces Acquisition of PQ Bypass, Inc.

Company Expands Vascular Reach to Treat Unmet Needs of Both AAA and PAD Patients IRVINE, Calif.—(BUSINESS WIRE)—April 13, 2021—Endologix LLC, a leader in the treatment of vascular disease, today announced it has completed the acquisition of PQ Bypass, Inc., a privately held medical technology compan…

Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System Outside of United States

The post Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System Outside of United States appeared first on Endologix.

Endologix announces first commercial implant of ALTO Abdominal Stent Graft System & official start of U.S. commercial release

The post Endologix announces first commercial implant of ALTO Abdominal Stent Graft System & official start of U.S. commercial release appeared first on Endologix.

Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System

The post Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System appeared first on Endologix.

Endologix, Inc. Comments on Recent FDA Update on Type III Endoleaks with AFX® Endovascular AAA System

The post Endologix, Inc. Comments on Recent FDA Update on Type III Endoleaks with AFX® Endovascular AAA System appeared first on Endologix.

Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants

The post Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants appeared first on Endologix.
Show more

Endologix Frequently Asked Questions

  • When was Endologix founded?

    Endologix was founded in 1992.

  • Who are Endologix key executives?

    Endologix's key executives are John Onopchenko, Cindy Pinto and Reyna Fernandez.

  • How many employees does Endologix have?

    Endologix has 528 employees.

  • What is Endologix revenue?

    Latest Endologix annual revenue is $143.4 m.

  • What is Endologix revenue per employee?

    Latest Endologix revenue per employee is $271.5 k.

  • Who are Endologix competitors?

    Competitors of Endologix include Micreos, Enanta Pharmaceuticals and Mcneil.

  • Where is Endologix headquarters?

    Endologix headquarters is located at 2 Musick, Irvine.

  • Where are Endologix offices?

    Endologix has offices in Irvine, Santa Rosa, Rosmalen, 's-Hertogenbosch and in 1 other location.

  • How many offices does Endologix have?

    Endologix has 5 offices.